Allergan Aesthetics, an AbbVie Company · 2 months ago
2026 Investigative Toxicology Complex In Vitro Models Intern (PhD)
AbbVie is a company dedicated to discovering and delivering innovative medicines and solutions. The Investigative Toxicology Intern will work within the Molecular Toxicology group to develop and apply in vitro models for evaluating compound toxicities, gaining experience in cellular and molecular biology techniques.
BeautyManufacturingPharmaceuticalWellness
Responsibilities
Execute and analyze experiments to evaluate drug-induced changes in expression
Use complex in vitro models to investigate toxicities associated with compounds
Work collaboratively with team members to design experiments and explore data
Communicate updates through written reports and oral presentations
Qualification
Required
Currently enrolled in university, pursuing a PhD in toxicology, cellular and molecular biology, or other related field
Must be enrolled in university for at least one semester following the internship
Must have familiarity with cellular and molecular biology
Preferred
Expected graduation date between December 2026 – June 2027
Experience with cell culture or complex in vitro models
Benefits
Competitive pay
Relocation support for eligible students
Select wellness benefits and paid holiday / sick time
Potential for publication co-authorship
Opportunity to connect with AbbVie leaders and scientists
Company
Allergan Aesthetics, an AbbVie Company
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products.
H1B Sponsorship
Allergan Aesthetics, an AbbVie Company has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2024 (1)
2023 (1)
2022 (16)
2021 (14)
2020 (5)
Funding
Current Stage
Late StageLeadership Team
Recent News
2025-12-04
Company data provided by crunchbase